Beffinger, Michal, Schellhammer, Linda, Taskoparan, Betül, Deplazes, Sereina, Salazar, Ulisse, Tatari, Nazanin, Seehusen, Frauke, von Balthazar, Leopold, Zinner, Carl Philipp, Spath, Sabine, Shekarian, Tala, Ritz, Marie-Françoise, McDaid, Marta, Egloff, Pascal, Zimmermann, Iwan, Okada, Hideho, Ward, E. Sally, Rohrer, Jack, Seeger, Markus A, Buch, Thorsten, Hutter, Gregor and vom Berg, Johannes (2025) FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma. Nature Communications, 16 (1), [4751]. (doi:10.1038/s41467-025-59971-0).
Abstract
Glioblastoma remains a challenging indication for immunotherapy: the bloodbrain barrier hampers accessibility for systemic treatments and the immunosuppressive microenvironment impedes immune attack. Intratumoral therapy with the proinflammatory cytokine interleukin-12 (IL-12) can revert immunosuppression but leakage into the circulation causes treatment-limiting toxicity. Here we engineer an IL-12Fc fusion cytokine with reduced binding to the neonatal Fc receptor FcRn. FcRn-silenced IL-12Fc avoids FcRn-mediated brain export, thus exhibits prolonged brain retention and reduced blood levels, which prevents toxicity. Inmurine glioblastoma, FcRn-silenced IL-12Fc induces more durable responses with negligible systemic cytokine exposure and boosts the efficacy of radio- and chemotherapy. It triggers anti-tumor responses independently of peripheral T cell influx or lymphopenia and leads to inflammatory polarization of the tumor microenvironment in patientderived glioblastoma explants. FcRn-silencing of IL-12Fc may unlock the full potential of IL-12 for brain cancer therapy and could be further applied to containing the activity of other therapeutics targeting neurological diseases.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.